JP2006519762A - アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法 - Google Patents
アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法 Download PDFInfo
- Publication number
- JP2006519762A JP2006519762A JP2005501148A JP2005501148A JP2006519762A JP 2006519762 A JP2006519762 A JP 2006519762A JP 2005501148 A JP2005501148 A JP 2005501148A JP 2005501148 A JP2005501148 A JP 2005501148A JP 2006519762 A JP2006519762 A JP 2006519762A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- peptide
- seq
- binds
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 183
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 45
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 title description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 265
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 116
- 150000001413 amino acids Chemical class 0.000 claims description 99
- 230000027455 binding Effects 0.000 claims description 72
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 31
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 31
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 28
- 210000004556 brain Anatomy 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 230000009260 cross reactivity Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 201000010374 Down Syndrome Diseases 0.000 abstract description 10
- 206010044688 Trisomy 21 Diseases 0.000 abstract description 9
- 229920001184 polypeptide Polymers 0.000 description 96
- 235000001014 amino acid Nutrition 0.000 description 93
- 229940024606 amino acid Drugs 0.000 description 91
- 108090000623 proteins and genes Proteins 0.000 description 80
- 210000004027 cell Anatomy 0.000 description 53
- 102000040430 polynucleotide Human genes 0.000 description 53
- 108091033319 polynucleotide Proteins 0.000 description 53
- 239000002157 polynucleotide Substances 0.000 description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
- 201000010099 disease Diseases 0.000 description 48
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 43
- 239000012634 fragment Substances 0.000 description 36
- 230000014509 gene expression Effects 0.000 description 35
- 210000004408 hybridoma Anatomy 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 32
- 239000000427 antigen Substances 0.000 description 31
- 239000003814 drug Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 239000013598 vector Substances 0.000 description 27
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 108060003951 Immunoglobulin Proteins 0.000 description 22
- 238000003556 assay Methods 0.000 description 22
- 102000018358 immunoglobulin Human genes 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 230000013595 glycosylation Effects 0.000 description 18
- 238000006206 glycosylation reaction Methods 0.000 description 18
- 210000001320 hippocampus Anatomy 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 230000004927 fusion Effects 0.000 description 16
- 210000005153 frontal cortex Anatomy 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 239000002502 liposome Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 239000000969 carrier Substances 0.000 description 12
- 239000012636 effector Substances 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 241000283984 Rodentia Species 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108010087819 Fc receptors Proteins 0.000 description 8
- 102000009109 Fc receptors Human genes 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 8
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000007917 intracranial administration Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000000274 microglia Anatomy 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- -1 tripeptide Chemical group 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000003496 anti-amnesic effect Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 230000007082 Aβ accumulation Effects 0.000 description 3
- 238000009010 Bradford assay Methods 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 3
- 108010035533 Drosophila Proteins Proteins 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 101710188053 Protein D Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 101710132893 Resolvase Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000001947 dentate gyrus Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108700020309 Drosophila amn Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101100428769 Pisum sativum BP80 gene Proteins 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 101150031224 app gene Proteins 0.000 description 2
- 208000013404 behavioral symptom Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940124452 immunizing agent Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 102220547923 ASNSD1 upstream open reading frame protein_G38A_mutation Human genes 0.000 description 1
- 102220546965 ASNSD1 upstream open reading frame protein_V36A_mutation Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical group [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 108010023260 immunoglobulin Fv Proteins 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000012142 reagent concentrate Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102200091761 rs33926449 Human genes 0.000 description 1
- 102220323077 rs940936212 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本願の種々の刊行物が(特許および特許出願を含む)全体にわたり引用されている。これら全体的な刊行物の開示が、本明細書により引用として取り入れられている。
本発明は、Aβペプチド(配列番号1)(表6)へ結合する単離されたモノクロナール抗体を提供する。より詳細には、Aβペプチドのアミノ酸1-16,16-28又は28-40へ結合する抗体が提供される。好ましくは抗体が、配列番号4,6,8又は10(表9および11)に示されたアミノ酸配列を有するモノクロナール抗体の結合を、又は8A1.2A1,3C6.1F9又は10B10.2E6として指定されたハイブリドーマにより産生されるモノクロナール抗体の結合を、競合的に阻害する。幾つかの例においてモノクロナール抗体が、約200nM以下、約100nM以下、約60nM以下、好ましくは約30nM以下、より好ましくは約3nM以下、約2nM以下、および約1nM以下の親和性により、Aβペプチドを結合する。幾つかの例においてモノクロナール抗体のFab断片が、約200nM以下、約100nM以下、約60nM以下、約30nM以下、約3nM以下、約2nM以下、および約1nM以下の親和性により、Aβペプチドを結合する。好ましい例において抗体が、そのAβエピトープに配列番号4,6,8又は10に示されるアミノ酸配列を有するモノクロナール抗体、又は8A1.2A1,3C6.1F9又は10B10.2E6にて指定されるハイブリドーマにより産生されるモノクロナール抗体が、結合する同じAβエピトープに結合する。
さらに本発明が、8A1.2A1,3C6.1F9又は10B10.2E6にて指定されるハイブリドーマにより産生されるモノクロナール抗体を提供する。所望により本明細書に記載されたモノクロナール抗体が、治療剤に結合されそして/又は検出可能な標識にて標識化することができる。
発明の詳細な説明
定義
同一を、そして好ましくは配列がこれと少なくとも90%同一であり、最も好ましくは配列がこれと少なくとも約95%同一であることが好ましくなる。
抗体
抗体の製造
多様なそして修飾された免疫反応ポリペプチドおよび抗体
アミノ酸の位置を、置換部位にて、又は置換部位にさらなる又はその他の変種(variant)を導入することにより正確にする。従ってアミノ酸配列の変種(variant)を導入する部位が予め定められるが、変異体それ自体の性質を予め定める必要がない。たとえば、所定の部位にて変異体の性能を分析するために、ala走査又は無作為な変異体の生成が標的ゴドン又は領域にて行われ、そして発現される抗体の変種(variant)が、所望の活性のためスクリーニングされる。
(a) たとえば、シート状、又はラセン形状として置換領域のペプチド骨格の構造、
(b) 標的部位における分子の荷電又は疎水性、又は
(C) 所定量の側鎖、
の維持に及ぼす影響において、有意に異なる置換体を選択することにより達成される。
天然に形成する残基は、共通の側鎖特性に基づく群に分割され、すなわち
(1) 疎水性:ノルロイシン、Met,Ala,Val,Leu,Ile;
(2) 中性親水性:Cys,Ser,Thr;
(3) 酸性の:Asp,Glu;
(4) 塩基性:Asn,Gln,His,Lys,Arg;
(5) 鎖の配列に影響する残基:Gly,Pro;および
(6) 芳香族:Trp,Tyr,Phe、
に分割される。
融合タンパク質
アミノ酸)、およびタンパク質D誘導体が、脂質化されても良い(lipidated)。特定の好ましい例において、リポタンパクD 融合パートナーの最初の109残基が、Nの末端上に含まれ、付加的な外因性T細胞エピトープを伴うポリペプチドを提供し、そして大腸菌の発現レベルを増大させる(従って、エンハンサーの発現として機能する)。脂質テイルが、抗原提示細胞へ抗原を最適に提示することを保障する。その他の融合パートナーは、インフルエンザ・ウイルス、NS1(ヘマグルチニン)からの非構造タンパク質を含む。T-ヘルパー・エピトープを含む異なる断片を用いることができるが、典型的にN-末端の81アミノ酸が用いられる。
ポリヌクレオチド、およびベクター
となるように、十分に長くそして十分明白なものにすべきである。オリゴヌクレオチドは、それがスクリーニングされたライブラリーにおけるDNAへ、ハイブリダイズにて検出できるように標識化することが好ましい。標識化する方法が、技術的に周知であり、そして32P-標識化されたATPなどの放射性標識の使用、ビオチン化又は酵素による標識化を含む。中程度のストリンジエント、および高いストリンジエントを含むハイブリダイゼーションの条件は、上記Sambrookらにて提供される。
医薬組成物
投与および投与量
抗体の診断的な使用
幾つかの例においてその抗体が、約60nM以下、約30nM以下又は約3nM以下の親和性にて、Aβペプチド(配列番号1)のアミノ酸39および/又は40を含むエピトープへ優先的に結合する。幾つかの例においてその抗体が、配列番号4および/又は6に示されるアミノ酸配列をモノクロナール抗体の結合、又は8A1.2A1に指定されたハイブリドーマにより産生されるモノクロナール抗体の結合を競合的に阻害する。幾つかの例において、その抗体が、配列番号4および/又は6に示されるアミノ酸配列を含む抗体と又は8A1.2A1に指定されたハイブリドーマにより産生されるモノクロナール抗体が結合するとAβペプチド(配列番号1)上同じエピトープへ結合する。幾つかの例において活性剤が、本明細書に記載されたヒト化(humanized)、キメラ抗体、又はヒト抗体のいずれかを含む。容器に付いている標識は、その組成物が、アルツハイマー病などの病理状態を治療又はAβ又はβAPPを検出又は精製に使用することを示し、さらに上記のものなどin vivoかin vitroのいずれかの使用を対象として指示している。
実施例
、Aβに対し高い親和性と特異的な抗体を、Aβ関連疾患を標的とする有益な治療剤として生成し、そして提供することを、本実施例に提示したデータが示している。Geerligs HJら、1989,J.Immunol.Methods 124:95-102;Kenney JSら、1989,J.Immunol.Methods 121:157-166;and Wicher Kら、1989,Int.Arch.Allergy Appl.Immunol.89:128-135に記載のように、マウスを、継続して10週の間隔で、Ribiアジュバント(足パッド当り50μl、マウス当り総量にて100μl)に50-100μgのAβ1-40のペプチドにて免疫化した。
モノクロナール抗体により認識されたAβポリペプチドのエピトープを判定するために、Surface Plaamon Resonance(SPR,Biacore 3000)結合分析を用いた。ビオチン(Global Peptide Services,CO)に結合したAβ1-40(配列番号1)を、ステップアビジン被覆チップ上に固定した。Aβペプチドの可溶性断片(at 1000nM,from American Peptide Company Inc.,CA)の存在又は非存在における、固定されたAβ1-40へAβ抗体(100nMにて)を結合する。モノクロナール抗体2324,2289および2286(これらそれぞれのハイブリドーマ細胞株10B10.2E6,3C6.1F9,and 8A1.2A1から単離されたより正確な抗体)の結合を、Aβ1-40へ置き換えるために必要とされるAβペプチドが、それぞれAβ1-16、β1-28、Aβ1-40である(図3)。3種の抗体全てのAβ1-40への結合することが、可溶性Aβ1-40により阻害される。しかしながら、Aβ1-38ペプチドが、Aβ1-40のMAbs 2324と2289への結合を阻害した、MAb2286を阻害しなかったことが、MAb2286が結合するエピトープが、Aβ1-40ペプチドのアミノ酸39および/又は40を含むことを示唆している(図3)。
マウスの抗体2286を、重鎖CDRs(Kabat and/or Chothia)をヒト生殖細胞受容体の配列VH3およびVH4へ移植することにより、ヒト化(humanized)した;そして軽鎖Kabat CDRsを、ヒト生殖細胞受容体の配列08に移植した。抗体2286のヒト化(humanized)重鎖および軽鎖を下記表4に示す。
本発明のモノクロナール抗体が、アルツハイマー病を治療し、そして防止するための有効な治療剤を提供することを、本例が示している。驚いたことにこれらのデータは、AβのC末端(すなわちaa 28-40)にて指向される抗体が、アルツハイマー病のこうしたマウス・モデルのN末端(aa 1-16)にて指向された抗体として、Aβ、チオフラビン-Sを清浄にし、そしてMHC-II染色の増大にまさに効果的である。その理由はAβのN末端を標的とする抗体が、前駆体を認識する能力の増大そして/又は集塊するアミロイド沈着の破壊に都合が良いと考えられ、これらの結果が、アルツハイマー病治療に有望な新らしい療法戦略を提供する。
小膠細胞の活性およびアミロイドの除去における抗Aβ抗体2286のFcドメインの潜在的役割を研究するために、小膠細胞の活性およびアミロイドの除去におけるショウジョウバエのタンパク質amnesiacに指向される抗体2286、無傷な抗体、コントロール・モノクロナール抗体のF(ab’)2断片の効果が、実施例6に記載された動物モデルにて比較され、その抗体が頭蓋内に投与された。
F (ab’)2 断片の調製
抗体画分の検討
外科的手術方法:
組織の調製
免疫組織化学法
データの分析:
結果:
アルツハイマー病トランジェニック・モデルマウスの全身的な受身免疫化後のモノクロナール抗体2286の効果を試験するために、本実験を行った。19ヶ月の年齢のTg2576のトランジェニック・マウス(Hsiaoら、1996,Science 274:99-102)を、モノクロナール抗体2286か、抗-健忘症抗体(IgG1コントロール)のいずれかにより、腹腔内へ注射した。抗体を、2ヶ月又は3ヶ月間、体重のKg当り10mgの投与量にて毎週1回1ヶ月注入し、その後Aβの血清濃度および血清中の抗-Aβ抗体の両方を測定した。
物質 抗体番号 ATCCアクセス番号 寄託日
8A1.2A1 2286 PTA-5199 May 15,2003
Claims (50)
- Aβ1-40のペプチド(配列番号1)のアミノ酸28-40へ優先的に結合する抗体、および医薬的に受け入れ可能な担体を含む医薬組成物の有効量を対象体へ投与することを含む、アルツハイマー病を治療する方法。
- 抗体が、Aβ1-40のペプチド(配列番号1)のアミノ酸39及び/又は40を含むエピトープへ優先的に結合する請求項1記載の方法。
- 抗体が、Aβ1-42ペプチドとAβ1-43ペプチドとの有意な交差反応性を示さない請求項1又は2のいずれか1項記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)へ結合する請求項1記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)へ結合する請求項1記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項2記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項2記載の方法。
- 抗体が、アミノ酸配列の配列番号4および6を含むモノクロナール抗体をAβ1-40のペプチド(配列番号1)へ結合することを競合的に阻害する請求項1記載の方法。
- 抗体が、配列番号4および6のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープへ結合する請求項1記載の方法。
- 抗体がモノクロナール抗体である請求項1記載の方法。
- 抗体がヒト化(humanized)抗体である請求項1記載の方法。
- 抗体がヒト抗体である請求項1記載の方法。
- Aβ1-40のペプチド(配列番号1)のアミノ酸28-40へ優先的に結合する抗体、および医薬的に受け入れ可能な担体を含む医薬組成物の有効量を対象体へ投与することを含む、対象体内のアミロイド斑の形成を阻害する方法。
- 抗体が、Aβ1-40のペプチド(配列番号1)のアミノ酸39及び/又は40を含むエピトープへ優先的に結合する請求項13記載の方法。
- 抗体が、Aβ1-42ペプチドおよびAβ1-43ペプチドとの有意な交差反応性を示さない請求項13記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)へ結合する請求項13記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項13記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項14記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項14記載の方法。
- 抗体が、配列番号4および6のアミノ酸配列を含むモノクロナール抗体を、Aβ1-40のペプチド(配列番号1)へ結合することを、競合的に阻害する請求項13記載の方法。
- 抗体が、配列番号4および6のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープへ結合する請求項13記載の方法。
- 抗体がモノクロナール抗体である請求項13記載の方法。
- 抗体がヒト化(humanized)抗体である請求項13記載の方法。
- 抗体がヒト抗体である請求項13記載の方法。
- アミロイド斑が、対象体の脳内にある請求項13記載の方法。
- Aβ1-40のペプチド(配列番号1)のアミノ酸28-40へ優先的に結合する抗体、および医薬的に受け入れ可能な担体を含む医薬組成物の有効量を対象体へ投与することを含む、対象体内のアミロイド斑を減少させる方法。
- 抗体が、Aβ1-40のペプチド(配列番号1)のアミノ酸39及び/又は40を含むエピトープへ優先的に結合する請求項26記載の方法。
- 抗体が、Aβ1-42ペプチドおよびAβ1-43ペプチドと有意な交差反応性を示さない請求項26記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)へ結合する請求項26記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項26記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項26記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項27記載の方法。
- 抗体が、配列番号4および6のアミノ酸配列を含むモノクロナール抗体を、Aβ1-40のペプチド(配列番号1)へ結合することを、競合的に阻害する請求項26記載の方法。
- 抗体が、配列番号4および6のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープへ結合する請求項26記載の方法。
- 抗体がモノクロナール抗体である請求項26記載の方法。
- 抗体がヒト化(humanized)抗体である請求項26記載の方法。
- 抗体がヒトの抗体である請求項26記載の方法。
- アミロイド斑が、対象体の脳内にある請求項26記載の方法。
- Aβ1-40ペプチド(配列番号1)のアミノ酸28-40へ優先的に結合する抗体、および医薬的に受け入れ可能な担体を含む医薬組成物の有効量を対象体に投与することを含む、対象体内におけるアルツハイマー病の関連した症状の発症を遅延させる方法。
- 抗体が、Aβ1-40のペプチド(配列番号1)のアミノ酸39及び/又は40を含むエピトープへ優先的に結合する請求項39記載の方法。
- 抗体が、Aβ1-42ペプチドおよびAβ1-43ペプチドと有意な交差反応性を示さない請求項39記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)へ結合する請求項39記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項39記載の方法。
- 抗体のFab断片が、約200nM以下の親和性にてAβ1-40のペプチド(配列番号1)を結合する請求項40記載の方法。
- 抗体のFab断片が、約1nM以下の親和性にてAβ1-40のペプチド(配列番号1)へ結合する請求項40記載の方法。
- 抗体が、配列番号4および6のアミノ酸配列を含むモノクロナール抗体がAβ1-40のペプチド(配列番号1)へ結合することを競合的に阻害する請求項39記載の方法。
- 抗体が、配列番号4および6のアミノ酸配列を含むモノクロナール抗体が結合するエピトープと同じエピトープへ結合する請求項39記載の方法。
- 抗体がモノクロナール抗体である請求項39記載の方法。
- 抗体がヒト化(humanized)抗体である請求項39記載の方法。
- 抗体がヒト抗体である請求項39記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41723202P | 2002-10-09 | 2002-10-09 | |
US44761103P | 2003-02-13 | 2003-02-13 | |
US46475403P | 2003-04-22 | 2003-04-22 | |
US48035303P | 2003-06-20 | 2003-06-20 | |
PCT/US2003/032080 WO2004032868A2 (en) | 2002-10-09 | 2003-10-09 | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006519762A true JP2006519762A (ja) | 2006-08-31 |
JP2006519762A5 JP2006519762A5 (ja) | 2006-11-16 |
Family
ID=32097078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501148A Withdrawn JP2006519762A (ja) | 2002-10-09 | 2003-10-09 | アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US20040146512A1 (ja) |
EP (1) | EP1633786A4 (ja) |
JP (1) | JP2006519762A (ja) |
KR (1) | KR20050071564A (ja) |
AU (1) | AU2003279216A1 (ja) |
BR (1) | BR0315157A (ja) |
CA (1) | CA2501945A1 (ja) |
MX (1) | MXPA05003621A (ja) |
NO (1) | NO20052220L (ja) |
PL (1) | PL377769A1 (ja) |
WO (1) | WO2004032868A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009104736A1 (ja) * | 2008-02-22 | 2009-08-27 | 財団法人ヒューマンサイエンス振興財団 | 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物 |
JP2011506387A (ja) * | 2007-12-11 | 2011-03-03 | グラクソ グループ リミテッド | 抗原結合タンパク質 |
JP2021529543A (ja) * | 2018-07-17 | 2021-11-04 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | 抗aベータ抗体、その抗原結合フラグメントおよびそれらの用途 |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2501945A1 (en) * | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
ES2246178B1 (es) * | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
KR20070040824A (ko) | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
US9907485B2 (en) | 2004-10-15 | 2018-03-06 | Brainlab Ag | Targeted immunization and plaque destruction against Alzheimer's disease |
WO2006081171A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
KR101401159B1 (ko) | 2005-12-12 | 2014-05-29 | 에프. 호프만-라 로슈 아게 | 가변 부위에 글리코실화를 가지는 아밀로이드 베타에 대한 항체 |
RU2551782C2 (ru) | 2005-12-12 | 2015-05-27 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
ATE451392T1 (de) * | 2006-03-30 | 2009-12-15 | Glaxo Group Ltd | Gegen amyloid-beta peptid gerichtete antikörper |
WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
EP2086538B1 (en) | 2006-10-27 | 2012-03-14 | Medivation Neurology, Inc. | Combination therapies for treating alzheimer's disease using dimebon and donepezil |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
US7939075B2 (en) | 2007-01-11 | 2011-05-10 | Philipps-Universitaet Marburg | Human monoclonal anti-amyloid-beta antibodies |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
US20090022728A1 (en) * | 2007-03-09 | 2009-01-22 | Rinat Neuroscience Corporation | Methods of treating ophthalmic diseases |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
EP2152309B1 (en) | 2007-05-14 | 2013-07-10 | Medtronic, Inc. | Methods and device to neutralize soluble toxic agents in the brain |
US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
EP2185591B1 (en) * | 2007-08-20 | 2014-05-14 | Glaxo Group Limited | Production method |
JP5500730B2 (ja) | 2007-09-13 | 2014-05-21 | デレネックス セラピューティクス アーゲー | β−アミロイドペプチドに対するヒト化抗体 |
EP2185592B1 (en) * | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
EP2586795B1 (en) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
EP2205632B1 (en) * | 2007-10-05 | 2016-11-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
EP2730659A3 (en) | 2007-12-28 | 2016-01-13 | Prothena Biosciences Limited | Treatment and Prophylaxis of Amyloidosis |
CA2730073A1 (en) * | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
MX2011000875A (es) | 2008-07-21 | 2011-04-05 | Probiodrug Ag | Ensayo de anticuerpo de diagnostico. |
US20100092470A1 (en) * | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
EP2691393B1 (en) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
US10112987B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
CN105732639A (zh) | 2012-06-29 | 2016-07-06 | 辉瑞大药厂 | 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类 |
JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
EP3030580A4 (en) | 2013-08-05 | 2017-04-05 | St. Vincent's Institute Of Medical Research | An antibody therapy for amyloid beta disease |
CA2925743C (en) | 2013-10-04 | 2018-03-06 | Pfizer Inc. | Novel bicyclic pyridinones as gamma-secretase modulators |
CN106068125B (zh) | 2013-12-17 | 2021-08-31 | Mhs克尔创新有限责任公司 | 治疗脂肪组织积聚的组合物和方法 |
EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
SG11201607465UA (en) | 2014-04-01 | 2016-10-28 | Pfizer | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
KR20180078347A (ko) | 2014-04-10 | 2018-07-09 | 화이자 인코포레이티드 | 2-아미노-6-메틸-4,4a,5,6-테트라히드로피라노[3,4-d][1,3]티아진-8a(8H)-일-1,3-티아졸-4-일 아미드 |
US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
KR102061952B1 (ko) | 2014-08-06 | 2020-01-02 | 화이자 인코포레이티드 | 이미다조피리다진 화합물 |
WO2016032949A1 (en) | 2014-08-26 | 2016-03-03 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
CN107001473B (zh) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
AU2015360579A1 (en) | 2014-12-10 | 2017-05-18 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
EP3253755B1 (en) | 2015-02-03 | 2020-08-26 | Pfizer Inc | Novel cyclopropabenzofuranyl pyridopyrazinediones |
JP6827959B2 (ja) | 2015-06-17 | 2021-02-10 | ファイザー・インク | 三環式化合物およびホスホジエステラーゼ阻害剤としてのそれらの使用 |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
BR112018003489A2 (pt) | 2015-09-24 | 2018-09-25 | Pfizer | n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
RU2753390C1 (ru) | 2015-10-02 | 2021-08-13 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения |
PT3419979T (pt) | 2016-02-23 | 2020-03-26 | Pfizer | Compostos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida |
KR102470497B1 (ko) | 2016-07-01 | 2022-11-23 | 화이자 인코포레이티드 | 신경계 및 신경변성 질환을 치료하기 위한 5,7-디히드로-피롤로-피리딘 유도체 |
AU2018230109B2 (en) | 2017-03-10 | 2022-05-12 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
US11312713B2 (en) | 2017-03-10 | 2022-04-26 | Pfizer Inc. | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors |
CN110997693A (zh) | 2017-06-07 | 2020-04-10 | 阿德克斯公司 | τ聚集抑制剂 |
WO2018234953A1 (en) | 2017-06-22 | 2018-12-27 | Pfizer Inc. | DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES |
EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
CA3073066A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
US11524954B2 (en) | 2018-03-23 | 2022-12-13 | Pfizer Inc. | Piperazine azaspiro derivatives |
US20220031867A1 (en) | 2018-10-04 | 2022-02-03 | University Of Rochester | Glymphatic delivery by manipulating plasma osmolarity |
TW202035442A (zh) | 2018-12-20 | 2020-10-01 | 美商建南德克公司 | 經修飾之抗體Fc及其使用方法 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4403112A (en) * | 1981-05-18 | 1983-09-06 | Modafferi Acoustical Systems, Ltd. | Phase shift low frequency loudspeaker system |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) * | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4891268A (en) * | 1984-03-26 | 1990-01-02 | Metal Coatings International Inc. | Coated metal substrates with anticorrosion coating composition |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) * | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8508845D0 (en) * | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) * | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US5525339A (en) * | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5219740A (en) * | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
US5422120A (en) * | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6673776B1 (en) * | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DK0546073T3 (da) * | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ATE164395T1 (de) * | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5278299A (en) * | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9114324D0 (en) * | 1991-07-03 | 1991-08-21 | Kontor Moulding Systems Ltd | Injection moulding of thermoplastic polymers |
CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010260A1 (en) * | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5851787A (en) * | 1992-04-20 | 1998-12-22 | The General Hospital Corporation | Nucleic acid encoding amyloid precursor-like protein and uses thereof |
TW327194B (en) * | 1992-05-01 | 1998-02-21 | American Cyanamid Co | Novel amyloid precursor proteins and methods of using same |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
WO1994009371A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US5955317A (en) * | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
EP0683234B2 (en) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
US6107050A (en) * | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DE69429925T2 (de) * | 1993-10-20 | 2002-10-02 | Univ Durham | METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID |
US6436908B1 (en) * | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
US5525126A (en) * | 1994-10-31 | 1996-06-11 | Agricultural Utilization Research Institute | Process for production of esters for use as a diesel fuel substitute using a non-alkaline catalyst |
US6114133A (en) * | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
EP0871720A2 (en) * | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
US6221645B1 (en) * | 1995-06-07 | 2001-04-24 | Elan Pharmaceuticals, Inc. | β-secretase antibody |
US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO1997012992A2 (en) * | 1995-10-02 | 1997-04-10 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US6107029A (en) * | 1996-07-31 | 2000-08-22 | Message Pharmaceticals, Inc. | Universal method for detecting interactions between RNA molecules and RNA binding proteins |
EP1006798A4 (en) * | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES |
US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
US6221670B1 (en) * | 1997-03-21 | 2001-04-24 | Scios Inc. | Methods to identify β-amyloid reducing agents |
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
EP2305709A1 (en) * | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
US20020086847A1 (en) * | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US6710226B1 (en) * | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6743427B1 (en) * | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
DK1078005T3 (da) * | 1998-05-21 | 2010-08-09 | Univ Tennessee Res Foundation | Fremgangsmåder til amyloidfjernelse ved anvendelse af anti-amyloidantistoffer |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
ATE355527T1 (de) * | 1999-05-03 | 2006-03-15 | Evotec Ag | Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit |
US6787637B1 (en) * | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
DK1409654T3 (da) * | 1999-06-16 | 2008-12-08 | Boston Biomedical Res Inst | Immunologisk styring af beta-amyloid-niveauer in vivo |
US6255054B1 (en) * | 1999-09-09 | 2001-07-03 | Jacques Hugon | Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease |
US6294171B2 (en) * | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
EP1353944A2 (en) * | 2000-04-05 | 2003-10-22 | The University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
EP1172378A1 (en) * | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US20040038302A1 (en) * | 2000-09-19 | 2004-02-26 | Roger Nitsch | Methods and compounds for treating brain amyloidosis |
US6573276B2 (en) * | 2001-05-09 | 2003-06-03 | Boehringer Ingelheim Pharma Kg | Muscarinic M1 agonist as an inhibitor of beta-amyloid (Aβ40 and Aβ42)-synthesis |
JP2005500389A (ja) * | 2001-08-17 | 2005-01-06 | イーライ・リリー・アンド・カンパニー | Aβに関連する病態および疾患を治療するための、可溶性Aβに高い親和性を有する抗体の使用 |
EP1469877A4 (en) * | 2001-11-02 | 2008-08-20 | Tanox Inc | B-cell lymphoma-specific antigen for use in the diagnosis and treatment of malignant B cell lesions |
EP1448601A4 (en) * | 2001-11-02 | 2006-04-26 | Diagenics Internat Corp | METHOD AND COMPOSITIONS OF MONOCLONAL ANTIBODIES SPECIFIC TO BETA-AMYLOIDE PROTEINS |
ATE419871T1 (de) * | 2002-04-25 | 2009-01-15 | Lilly Co Eli | Verfahren zur behandlung von angststörungen bei älteren personen |
CA2501945A1 (en) * | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
KR20070040824A (ko) * | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
-
2003
- 2003-10-09 CA CA002501945A patent/CA2501945A1/en not_active Abandoned
- 2003-10-09 JP JP2005501148A patent/JP2006519762A/ja not_active Withdrawn
- 2003-10-09 EP EP03770709A patent/EP1633786A4/en not_active Withdrawn
- 2003-10-09 BR BR0315157-3A patent/BR0315157A/pt not_active IP Right Cessation
- 2003-10-09 US US10/683,815 patent/US20040146512A1/en not_active Abandoned
- 2003-10-09 WO PCT/US2003/032080 patent/WO2004032868A2/en active Search and Examination
- 2003-10-09 PL PL377769A patent/PL377769A1/pl not_active Application Discontinuation
- 2003-10-09 KR KR1020057006180A patent/KR20050071564A/ko not_active Application Discontinuation
- 2003-10-09 MX MXPA05003621A patent/MXPA05003621A/es not_active Application Discontinuation
- 2003-10-09 AU AU2003279216A patent/AU2003279216A1/en not_active Abandoned
-
2005
- 2005-05-06 NO NO20052220A patent/NO20052220L/no not_active Application Discontinuation
-
2007
- 2007-01-12 US US11/652,821 patent/US20070160616A1/en not_active Abandoned
-
2010
- 2010-06-30 US US12/827,844 patent/US20110038861A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011506387A (ja) * | 2007-12-11 | 2011-03-03 | グラクソ グループ リミテッド | 抗原結合タンパク質 |
JP2014177462A (ja) * | 2007-12-11 | 2014-09-25 | Glaxo Group Ltd | 抗原結合タンパク質 |
WO2009104736A1 (ja) * | 2008-02-22 | 2009-08-27 | 財団法人ヒューマンサイエンス振興財団 | 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物 |
JPWO2009104736A1 (ja) * | 2008-02-22 | 2011-06-23 | 田平 武 | 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物 |
JP2021529543A (ja) * | 2018-07-17 | 2021-11-04 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | 抗aベータ抗体、その抗原結合フラグメントおよびそれらの用途 |
JP7436449B2 (ja) | 2018-07-17 | 2024-02-21 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 抗aベータ抗体、その抗原結合フラグメントおよびそれらの用途 |
Also Published As
Publication number | Publication date |
---|---|
US20110038861A1 (en) | 2011-02-17 |
EP1633786A2 (en) | 2006-03-15 |
US20040146512A1 (en) | 2004-07-29 |
KR20050071564A (ko) | 2005-07-07 |
BR0315157A (pt) | 2005-08-09 |
MXPA05003621A (es) | 2005-10-19 |
PL377769A1 (pl) | 2006-02-20 |
AU2003279216A1 (en) | 2004-05-04 |
EP1633786A4 (en) | 2007-07-25 |
US20070160616A1 (en) | 2007-07-12 |
WO2004032868A2 (en) | 2004-04-22 |
NO20052220D0 (no) | 2005-05-06 |
CA2501945A1 (en) | 2004-04-22 |
WO2004032868A3 (en) | 2006-06-22 |
NO20052220L (no) | 2005-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006519762A (ja) | アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法 | |
JP4280300B2 (ja) | アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法 | |
JP5042828B2 (ja) | アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法 | |
JP4997239B2 (ja) | 抗cd26抗体およびその使用方法 | |
KR100767146B1 (ko) | Aβ 펩티드를 격리시키는 인간화 항체 | |
RU2426744C2 (ru) | Антитела к ox40l и способы их применения | |
RU2432362C2 (ru) | Моноклональные антитела и их применения | |
CA2478049C (en) | Humanized antibodies that recognize beta amyloid peptide | |
TWI449535B (zh) | 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途 | |
EP1838348A1 (en) | Humanized amyloid beta antibodies for use in improving cognition | |
EA031698B1 (ru) | Человеческие анти-тау антитела | |
ZA200502610B (en) | Method of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof | |
MX2008000884A (en) | Anti-cd26 antibodies and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060921 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060921 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071011 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071011 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090105 |